Capital Fund Management (CFM)
VKTX icon

Capital Fund Management (CFM)’s Viking Therapeutics VKTX Stock Holding History

Capital Fund Management (CFM)’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.93M Buy
75,216
+54,392
+261% +$1.76M 0.01% 1204
2026
Q1 		$678K Buy
20,824
+9,098
+78% +$292K ﹤0.01% 1809
2025
Q4 		$413K Buy
+11,726
New +$415K ﹤0.01% 2251
2024
Q4 		– Sell
-75,767
Closed -$4.32M – 2264
2024
Q3 		$4.8M Sell
75,767
-5,042
-6% -$296K 0.01% 1038
2024
Q2 		$4.28M Buy
80,809
+30,015
+59% +$1.97M 0.01% 1021
2024
Q1 		$4.17M Sell
50,794
-213,469
-81% -$9.5M 0.01% 1135
2023
Q4 		$4.92M Sell
264,263
-7,587
-3% -$99.2K 0.01% 1098
2023
Q3 		$3.01M Buy
+271,850
New +$3.89M 0.01% 1187
2020
Q1 		– Sell
-27,294
Closed -$219K – 2051
2019
Q4 		$219K Buy
+27,294
New +$199K ﹤0.01% 1725

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Capital Fund Management (CFM)'s VKTX Position: Q2 2026 in Review

Capital Fund Management (CFM) increased its Viking Therapeutics (VKTX) stake by 261% in Q2 2026, buying an estimated $1.76M and bringing the position to 75,216 shares worth $2.93M. The position accounts for 0.01% of the portfolio, ranked #1204.

Capital Fund Management (CFM) first reported a position in VKTX in Q4 2019 and has held it in 9 quarters since. The position peaked at $4.92M in Q4 2023. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Capital Fund Management (CFM) held 75,216 shares of Viking Therapeutics worth $2.93M as of Q2 2026.
  • Capital Fund Management (CFM) bought 54,392 Viking Therapeutics shares in Q2 2026, an estimated $1.76M.
  • Viking Therapeutics made up 0.01% of Capital Fund Management (CFM)'s portfolio in Q2 2026, its #1204 holding.
  • Capital Fund Management (CFM) first reported a position in Viking Therapeutics in Q4 2019 and has held it in 9 quarters since.
  • Capital Fund Management (CFM)'s Viking Therapeutics position peaked at $4.92M in Q4 2023.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2026, filed 13 Aug 2026.